Evidence map›Paper›PMID 39363890›Full record

ArticleNAR genomics and bioinformatics2024

Exploring public cancer gene expression signatures across bulk, single-cell and spatial transcriptomics data with signifinder Bioconductor package.

Stefania Pirrotta, Laura Masatti, Anna Bortolato, Anna Corrà, Fabiola Pedrini, Martina Aere, Giovanni Esposito, Paolo Martini, Davide Risso, Chiara Romualdi and 1 more

Abstract read
In one paragraph

Article in NAR genomics and bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Stefania PirrottaDepartment of Biology, University of Padua, Padua 35121, Italy.
Laura MasattiDepartment of Biology, University of Padua, Padua 35121, Italy.
Anna BortolatoDepartment of Biology, University of Padua, Padua 35121, Italy.
Anna CorràFondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua 35127, Italy.
Fabiola PedriniInstitute of Pathology, University Hospital Heidelberg, Heidelberg 69120, Germany.
Martina AereDepartment of Biology, University of Padua, Padua 35121, Italy.
Giovanni EspositoImmunology and Molecular Oncology Diagnostic Unit of The Veneto Institute of Oncology IOV - IRCCS, Padua 35128, Italy.
Paolo MartiniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.
Davide RissoDepartment of Statistical Sciences, University of Padua, Padua 35121, Italy.
Chiara RomualdiDepartment of Biology, University of Padua, Padua 35121, Italy.ORCID https://orcid.org/0000-0003-4792-9047
Enrica CaluraDepartment of Biology, University of Padua, Padua 35121, Italy.ORCID https://orcid.org/0000-0001-8463-2432

Funding

Cancer Genomics:Integrative and Scalable Solutions in R / BioconductorU24CA180996 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MORGAN, MARTIN T, WALDRON, LEVI · 2014 to 2023
$6.9M
NCI NIH HHS U24 CA180996
6 · The paper itself

Abstract

Understanding cancer mechanisms, defining subtypes, predicting prognosis and assessing therapy efficacy are crucial aspects of cancer research. Gene-expression signatures derived from bulk gene expression data have played a significant role in these endeavors over the past decade. However, recent advancements in high-resolution transcriptomic technologies, such as single-cell RNA sequencing and spatial transcriptomics, have revealed the complex cellular heterogeneity within tumors, necessitating the development of computational tools to characterize tumor mass heterogeneity accurately. Thus we implemented signifinder, a novel R Bioconductor package designed to streamline the collection and use of cancer transcriptional signatures across bulk, single-cell, and spatial transcriptomics data. Leveraging publicly available signatures curated by signifinder, users can assess a wide range of tumor characteristics, including hallmark processes, therapy responses, and tumor microenvironment peculiarities. Through three case studies, we demonstrate the utility of transcriptional signatures in bulk, single-cell, and spatial transcriptomic data analyses, providing insights into cell-resolution transcriptional signatures in oncology. Signifinder represents a significant advancement in cancer transcriptomic data analysis, offering a comprehensive framework for interpreting high-resolution data and addressing tumor complexity.

Identifiers

PMID39363890
PMCPMC11447528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.